论文部分内容阅读
目的:观察吡格列酮对初诊2型糖尿病病人的疗效及安全性。方法:选取初诊的2型糖尿病病人42例,予吡格列酮15～30mg,口服,每日1次,连服12周。治疗前、后检测空腹和餐后2小时血糖、胰岛素水平,计算胰岛素敏感指数,同时检测糖化血红蛋白A1c、血脂水平,监测血压、腰围、肝功能、肾功能及血、尿常规。结果:治疗前空腹血糖、餐后2小时血糖、空腹胰岛素、餐后2小时胰岛素、胰岛素敏感指数分别为(8.6±1.0)mmol/L、(12.5±2.2)mmol/L、犤16～52(25)犦mU/L、犤58～160(103)犦mU/L、-10.3±0.7,治疗后分别为(6.5±0.9)mmol/L、(8.2±1.2)mmol/L、犤10～38(14)犦mU/L、犤36～113(82)犦mU/L、-4.7±0.4,治疗前后差异有统计学意义(P<0.05～0.01),无明显不良反应。结论:吡格列酮单药治疗初诊2型糖尿病安全、有效。
Objective: To observe the efficacy and safety of pioglitazone in newly diagnosed type 2 diabetic patients. Methods: Forty-two newly diagnosed type 2 diabetic patients were randomly assigned to receive pioglitazone 15-30 mg once daily for 12 weeks. Fasting and postprandial 2-hour blood glucose and insulin levels were measured before and after treatment. Insulin sensitivity index was calculated. Glycated hemoglobin A1c, blood lipid level, blood pressure, waist circumference, liver function, renal function, blood and urine were also measured. Results: Before treatment, fasting blood glucose, fasting blood glucose and fasting insulin at 2 hours postprandial, and insulin and insulin sensitivity index at 2 hours postprandial were (8.6 ± 1.0) mmol / L, 12.5 ± 2.2 mmol / L and 16-52 (6.5 ± 0.9) mmol / L, (8.2 ± 1.2) mmol / L and (10 ± 38) mmol / L, respectively (14) 犦 mU / L, ~ 36 ~ 113 (82) 犦 mU / L and -4.7 ± 0.4. The difference was statistically significant before and after treatment (P <0.05-0.01), with no obvious adverse reactions. Conclusions: Pioglitazone monotherapy is safe and effective in newly diagnosed type 2 diabetes mellitus.